Vernalis’ drug discovery platform to be used on an undisclosed oncology target.

Vernalis and Servier entered into a joint, three-year, oncology drug discovery collaboration. Under the terms of the collaboration, which utilizes Vernalis’ drug discovery platform on an undisclosed target, Vernalis will receive an upfront payment and a share in the downstream success of the product.

“The partnership with Vernalis is a major step in our strategy to increase our efforts in the development of novel anti-cancer therapeutic approaches,” remarks Emmanuel Canet, M.D., Ph.D., vp Servier R&D. “This collaboration will expedite the discovery of innovative compounds with potential use in therapeutic indications with high unmet medical need.”

Previous article“Miracle Medicines: Seven Lifesaving Drugs and the People Who Created Them.” by Robert Shook
Next articleNano-Terra and 3M Enter Nanotech Partnership